• Теги
    • избранные теги
    • Компании160
      • Показать ещё
      Разное33
      • Показать ещё
      Страны / Регионы52
      • Показать ещё
      Международные организации4
      Показатели4
      Сферы1
      Люди3
      Издания2
Astellas Pharma
Выбор редакции
29 ноября, 14:31

Гендиректор "Драгон Капитал" Фиала в третий раз стал президентом Европейской бизнес ассоциации

Обновленное правление Европейской бизнес ассоциации (ЕБА) 28 ноября избрало президентом генерального директора и основателя инвестиционной компании "Драгон Капитал" Томаша Фиалу, который после годичной паузы в третий раз возглавил ассоциацию.

25 ноября, 18:02

Intro Guide to the Fidelity Pacific Basin (FPBFX) Fund

Fidelity Pacific Basin Fund (FPBFX) a Zacks Rank #2 (Buy) was incepted in October 1986 and is managed by Fidelity Group

24 ноября, 07:33

Ситуация на фондовых площадках Азиатско-Тихоокеанского региона:

Основные фондовые индексы Азиатско-Тихоокеанского региона торгуются разнонаправленно. Большинство азиатских фондовых рынков упали в четверг, как оптимистичные экономические данные укрепили перспективу для более высоких процентных ставок в США. Акции на фондовых рынках Австралии торговались в зеленой зоне. Котировки в Китае находились около нулевой черты. Цены на акции на крупнейшей в Азии Токийской фондовой бирже растут, достигнув одиннадцатимесячного максимума на фоне подъема в Нью-Йорке. продолжающееся укрепление курса доллара к иене также очень положительно сказывается на настроении инвесторов, поскольку повышает прибыль крупных местных корпораций, ориентирующихся на внешние рынки. Напомним, вчера японские рынки были закрыты и сегодня перспективы выручки экспортеров улучшились. Автопроизводители были востребованы. Акции Toyota Motor Corp подорожали на 3,3%, а Honda Motor Co - на 3,0%. С другой сторона производители лекарств понесли убытки. Рыночная стоимость Takeda Pharmaceutical снизилась на 0,9%, Astellas Pharma потеряли 0,5 стоимость акций, а ценные бумаги Eisai Co рухнули на 5%. Nikkei 225 18,338.85 +175.91 +0.97% Shanghai Composite 3,247.24 +6.10 +0.19% S&P/ASX 200 5,479.70 -4.66 -0.08%Источник: FxTeam

07 ноября, 16:39

Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure

Both Pfizer (PFE) and Allergan fell short of expectations while reporting Q3 earnings results. Meanwhile, the industry remains under drug pricing pressure.

Выбор редакции
21 сентября, 21:35

ФАС выявила препараты, цены на которые в России выше минимальных цен в других странах

Федеральная антимонопольная служба (ФАС) установила случаи завышения цен на ряд лекарственных препаратов из списка программы госзакупки лекарств «7 нозологий». Как отмечается в сообщении ведомства, цены на ряд лекарств в России оказались выше минимальных цен в некоторых других странах мира. В частности, предельные цены по 48 позициям лекарственных препаратов, зарегистрированным в России, оказались в среднем выше на 39%, чем в других странах мира. В этот список попали препараты компании Astellas Pharma, Johnson & Johnson, Novartis, Teva, Roche, KRKA, Celgene.

21 сентября, 21:35

ФАС выявила препараты, цены на которые в России выше минимальных цен в других странах

Федеральная антимонопольная служба (ФАС) установила случаи завышения цен на ряд лекарственных препаратов из списка программы госзакупки лекарств «7 нозологий». Как отмечается в сообщении ведомства, цены на ряд лекарств в России оказались выше минимальных цен в некоторых других странах мира. В частности, предельные цены по 48 позициям лекарственных препаратов, зарегистрированным в России, оказались в среднем выше на 39%, чем в других странах мира. В этот список попали препараты компании Astellas Pharma, Johnson & Johnson, Novartis, Teva, Roche, KRKA, Celgene.

Выбор редакции
20 сентября, 23:16

Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study

Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.

05 сентября, 15:38

Drug Stocks Remain in Focus as Pricing Debate Continues

Mylan (MYL) finds itself in troubled waters with lawmakers now questioning Medicaid rebates for EpiPen.

23 августа, 11:50

Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)

Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.

Выбор редакции
23 августа, 00:06

Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?

Pfizer is paying $14 billion for Medivation Inc, but is it worth it?

22 августа, 19:10

Pfizer paying US$14b for Medivation

PFIZER will pay about US$14 billion in cash for cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio. The New York drugmaker

22 августа, 15:31

Pfizer to Buy Medivation for $14B, Boost Cancer Franchise

Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.

22 августа, 14:27

Another Big Pharma Merger

Pfizer says it’s buying Medivation for $14 billion.

22 августа, 13:58

Pfizer Acquires Prostate Drug Maker Medivation For $81.50, 21% Premium To Closing

As was leaked over the weekend, first by the FT, moments ago Pfizer, still stinging from its foiled mega-acquisition of Allergan earlier in the year, announced it would acquire prostate-cancer drug maker Medivation for $81.50, a 21% premium to the Friday closing price, in a $14 billion deal. Before the Pfizer deal was announced, there had long been speculation that MDVN would be acquired as Medivation was one of the few independent biotech companies left with a cancer treatment that is already approved and selling well. CEO David Hung says he decided to found the company after watching a 28-year-old breast-cancer patient die during his oncology fellowship. The firm's blockbuster drug, Xtandi has held its own against a rival prostate-cancer treatment from Johnson & Johnson called Zytiga. Xtandi could be one of the top-selling cancer drugs by 2020, according to EvaluatePharma. The move will add "one of the crown jewels of the multibillion-dollar market for cancer drugs to Pfizer’s portfolio." The impetus behind the transaction is that Medivation’s drug, Xtandi, already generates about $2 billion in yearly sales and has the potential to more than double, according to analysts. Pfizer has been seeking to expand its lineup of such oncology treatments. Xtandi would give the New York drug company a beachhead in prostate cancer complementing its breast-cancer treatment Ibrance, which is on track to be a blockbuster. Further, as the WSJ adds, Medivation’s drugs in development could also complement Pfizer’s efforts to develop combinations of cancer agents with so-called immunotherapies, which deploy the immune system in the fight against cancer. The acquisition would also further Pfizer CEO Ian Read’s efforts to bolster what he refers to as the innovative side of the company’s business. Read has said Pfizer would decide by year’s end whether to split into two, with one company selling fast-growing brand-name drugs like Ibrance and another selling drugs that have lost patent protection. The full press release below. Pfizer to Acquire Medivation Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter Pfizer Inc. (PFE) and Medivation, Inc. (MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance. "The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer," said Ian Read, Chairman and Chief Executive Officer, Pfizer. "The addition of Medivation will strengthen Pfizer's Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over the long-term. This transaction is another example of how we are effectively deploying our capital to generate attractive returns and create shareholder value." Medivation's portfolio includes XTANDI® (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell. XTANDI is the leading novel hormone therapy in the United States today and generated approximately $2.2 billion in worldwide net sales over the past four quarters, as recorded by Astellas Pharma Inc., with whom Medivation entered an agreement in 2009 to develop XTANDI globally and commercialize jointly in the U.S. Since its approval for advanced metastatic prostate cancer by the U.S. Food and Drug Administration in 2012, XTANDI has treated 64,000 men to date in the U.S. alone. Medivation and Astellas have built a robust development program for XTANDI, including two Phase 3 studies in non-metastatic prostate cancer and another Phase 3 study in hormone-sensitive prostate cancer. It is also being further developed in Phase 2 studies for the potential treatment of advanced breast cancer and hepatocellular carcinoma. In addition, Medivation has a promising, wholly-owned, late-stage oncology pipeline, which includes two development-stage oncology assets, talazoparib and pidilizumab. Talazoparib, currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer, has the potential to be a highly potent PARP inhibitor and could be efficacious across several additional tumors. Pidilizumab is an immune-oncology (IO) asset being developed for diffuse large B-cell lymphoma and other hematologic malignancies and has the potential to be combined with IO therapies in Pfizer's portfolio. "We believe the combination with Pfizer is the right next step in our growth trajectory and is a testament to the passion and dedication by which the Medivation team has delivered on our mission to profoundly transform patients' lives through medically innovative therapies," said David Hung, M.D., founder, president and CEO of Medivation. "This compelling transaction will deliver significant and immediate value to our stockholders and provides new opportunities for our employees as part of a larger company. We believe that Pfizer is the ideal partner to extend the reach of our blockbuster XTANDI franchise and take our promising, late-stage assets -- talazoparib and pidiluzimab -- to their next stages of development so that they can be made available to patients as quickly as possible." "The proposed acquisition of Medivation will build upon Pfizer's success with our IBRANCE® (palbociclib) launch in HR+/HER2- metastatic breast cancer and with our strong immuno-oncology portfolio, and will transform Pfizer into a leading oncology company," said Albert Bourla, Group President, Pfizer Innovative Health. "IBRANCE and XTANDI are anchor brands in breast and prostate cancer respectively, giving Pfizer leadership in two hormone-driven cancers. Similar to IBRANCE in the breast cancer setting, XTANDI is being explored for its potential to move from metastatic prostate cancer to treat earlier stages of non-metastatic prostate cancer. In addition, Medivation's portfolio within prostate cancer and across diverse tumors will complement Pfizer's broad IO portfolio. Finally, Medivation adds commercial scale to better compete with other top tier oncology companies in advance of the potential emergence of Pfizer's IO pipeline expected in the next few years. Together, we believe Pfizer and Medivation can bring the full force of our combined research and resources to combat two of the most common cancers, as well as speed cures and make accessible breakthrough medicines to patients, redefining life with cancer." Cancer remains the second leading cause of death in the U.S. and a "Top 10" killer worldwide. According to the American Cancer Society, breast cancer and prostate cancer are among the top three cancers by annual incidence in the U.S. There are several parallels between breast and prostate cancer, including the incidence of prostate cancer in the U.S., which is similar to that of breast cancer with approximately 280,000 cases per year. Pfizer expects to finance the transaction with existing cash. Under the terms of the merger agreement, a subsidiary of Pfizer will commence a cash tender offer to purchase all of the outstanding shares of Medivation common stock for $81.50 per share, net to the seller in cash, without interest, subject to any required withholding of taxes. The closing of the tender offer is subject to customary closing conditions, including U.S. antitrust clearance and the tender of a majority of the outstanding shares of Medivation common stock. The merger agreement contemplates that Pfizer will acquire any shares of Medivation that are not tendered into the offer through a second-step merger, which will be completed promptly following the closing of the tender offer. Pfizer expects to complete the acquisition in the Third- or Fourth-Quarter 2016. Pfizer's financial advisors for the transaction were Guggenheim Securities and Centerview Partners, with Ropes & Gray LLP acting as its legal advisor. J.P. Morgan Securities and Evercore served as Medivation's financial advisors, while Cooley LLP and Wachtell, Lipton, Rosen & Katz served as its legal advisors.

18 августа, 17:13

Cytokinetics' Amyotrophic Lateral Sclerosis Study Enrolled

Cytokinetics (CYTK) reported that it has completed patient enrollment in the phase III amyotrophic lateral sclerosis study on tirasemtiv.

Выбор редакции
21 июля, 04:06

Here's How It Works: Industry, Lawmakers And Money Mingle In Cleveland

by Ashley Balcerzak and Robert Maguire House Speaker Paul Ryan (R-Wisc.) poses with two employees at Pfizer, one of the many pharmaceutical industry sponsors of an RSLC fundraising event in Cleveland. (Photo: Ashley Balcerzak, OpenSecrets.org) House Speaker Paul Ryan's impassioned speech to unite the GOP on Tuesday was not the last he would give in Cleveland. A national Republican organization brought in the big guns for their fundraiser, with Ryan headlining the event to inspire donations. In the tranquility of the Cleveland Botanical Gardens on Wednesday, miles away from the madness surrounding the Quicken Loans Arena, Ryan stressed the need to coordinate and strengthen the Republican party on the state, local and federal levels. His audience? A bevy of state legislative leaders rubbing elbows with industry interests. The afternoon of cocktails and hors d'oeuvres was organized by the Republican Legislative Campaign Committee, part of the Republican State Leadership Committee, a national 527 political organization that aims to elect down-ballot Republicans.   The two-hour catered event treated politicians and their corporate guests to salmon-wrapped asparagus, watermelon topped with bleu cheese and edible flowers, and two open bars. (Note to watchdogs: This probably was ethically fine for Ryan and any other federal lawmakers there.) Republican officials and representatives of GOP-aligned big money groups like American Crossroads milled about chatting with corporate officials representing some of the biggest corporations in the country, from industries as diverse as tech and retail to fossil fuels and private prisons. The Republican State Leadership Committee brought state level politicians together with industry special interests for a fundraiser at the Cleveland Botanical Garden. (Photo: Robert Maguire, CRP) Reporters for the OpenSecrets Blog were not on the invitation list, but were able to gain access to the event. "Your help, your donations, your efforts to help in our states to maintain these majorities to continue to move us forward, is extremely important," said Ohio House Speaker Cliff Rosenberger, kicking off the event. "And by the way, before you go, make sure you see us again to see how much money we can get from you." Together, the more than two dozen corporations and organizations sponsoring the event have given $12.4 million to the RSLC's efforts since 2013. More than half of that came from just two donors: the U.S. Chamber of Commerce, $5.4 million, and the Altria Group, which gave nearly $1.2 million. Republicans are not alone in raising cash from corporations that hope to curry favor with legislators who will be formulating policies that will affect their bottom line. The RSLC's analog on the left, the Democratic Legislative Campaign Committee, raises millions from unions and corporations, and Democratic leaders will almost certainly be wooing these groups next week in Philadelphia. Very few of the sponsors at this morning's RSLC event, however, have been as generous with the DLCC. In all, those same sponsors only gave $2.3 million to the DLCC since 2013, and 11 have not given a single contribution to the Democratic group in that time frame. On average, the corporations sponsoring the Paul Ryan event favor the RSLC more than eight to one over the DLCC, with only four companies -- Wal-Mart, AT&T, Monsanto, and Microsoft -- having a near even split in support for both. Early in his speech, Ryan gave a nod to fossil fuel interests present, such as the American Coalition for Clean Coal and Electricity, a sponsor, and the American Fuel & Petrochemical Manufacturers, on the invitee list, in the middle of a metaphor about government effectiveness. "In the House we sort of see ourselves at the bottom of a ship, shoveling coal into the engine," Ryan said. "By the way, there's nothing wrong with shoveling coal into an engine. Shout out to coal country," he said, as the crowd burst into applause. Ryan concluded by emphasizing that the party needs resources to "make sure the down ticket stays strong" and maintain a "big and deep party" on all levels of government. Rep. Paul Ryan (R-Wisc.) headlined the RSLC event, expressing the importance of resources to Republican efforts. Big Pharma had a strong showing, with event backing from Astellas Pharma, Pfizer, Novartis and Teva Pharmaceutical Industries. The pharmaceutical manufacturing industry as a whole has been a big supporter of the RSLC, giving more than $3.4 million since 2013. Other notable sponsors include two of the largest private prison corporations, Corrections Corporation of America (which gave $53,000 since 2013) and the GEO Group. OpenSecrets Blog reporters also spied nametags laid out for foreign dignitaries, including Nigel Farage, Brexit leader and former head of the U.K. Independence Party, and Ron Dermer, the Israeli ambassador to the U.S. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

17 июня, 07:50

Не хватает привлекательности: что мешает развитию бизнеса в Украине

Ни предыдущему, ни нынешнему правительству похвастаться в улучшении инвестиционного климата в Украине нечем. 78% компаний не довольны бизнес-средой, а индекс привлекательности страны для капиталовложений находится на уровне начала 2014 года. Несмотря на множество обещаний власти, большинство бизнесменов до сих пор констатируют отсутствие каких-либо изменений, нулевой прогресс в реформах и сохранение коррупции...

08 апреля, 18:50

Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data

Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.